Combination Therapy for Fit (Younger and Older) Newly Diagnosed Multiple Myeloma Patients: Data Support Carfilzomib, Lenalidomide and Dexamethasone Independent of Cytogenetic Risk Status

I was given the task of supporting the use of carfilzomib, lenalidomide and dexamethasone (KRd) as therapy for patients with a new diagnosis of multiple myeloma (MM). I will argue KRd is well in line with modern treatment goals for MM: rapid, deep and sustainable treatment effect, with limited toxicity. Based on available data on its efficacy and safety profile, in the U.S., I would conjecture KRd will replace bortezomib, lenalidomide and dexamethasone (RVd) as the standard of care for “fit patients” with a new diagnosis of MM [1].
Source: Seminars in Oncology - Category: Cancer & Oncology Authors: Source Type: research